References in periodicals archive ?
(NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the presentation of new data from the company's Prepare trial, a global Phase 3 clinical trial of ResVax, an aluminum adjuvanted respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine.
Novavax (NVAX), up 10% after announcing it will utilize the accelerated approval pathway for licensure for NanoFlu, its nanoparticle seasonal influenza vaccine candidate.
MIPI Momenta Pharmaceutical MNTA Mylan, Inc MYL Myriad Genetics MYGN NabiBiopharma NABI Nektar Therapeutics NKTR Neurocrine Biosciences NBIX Neurogesx, Inc NGSX Nexmed, Inc NEXM Novavax, Inc NVAX NovenPharma, Inc NOVN NPS Pharma, Inc NPSP NymoxPhamaceutical NYMX Obagi Medical Products OMPI OncogenexPharma OGXI Oncothyreon, Inc
Novavax Inc (NVAX) shares advanced 1.62 percent to $ 2.51 in post-market trading.
* Novavax, Inc.(NASDAQ: NVAX) shares fell 8.5% to close at $6.67.
(NASDAQ: NVAX), is a late-stage biotechnology company that drives improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.
Novavax expects that upon the opening of trading on May 10, its common stock will trade on the Nasdaq Global Select Market on a split-adjusted basis under the current trading symbol "NVAX."
Novavax Inc (NVAX) slumped 2.42 percent to $2.02 in the post-market trading, Friday.
* Novavax, Inc.(NASDAQ: NVAX) shares declined 10.2% to $6.55.
(NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the second quarter and six months ended June 30, 2019.
Novavax (NVAX), up 8% after announcing positive results for NanoFlu.
Acronyms browser ?
Full browser ?